NEW Australian Public Assessment Reports (AusPARs) have been released for three products now listed on the Australian Register of Therapeutic Goods.
The documents detail the approval processes for HIV oral therapy Biktarvy, (bictegravir/emtricitabine/tenofovir alafenamide) from Gilead Sciences, as well as the extension of indications for AstraZeneca's Tagrisso (osimertinib mesilate) for non-small cell lung cancer.
There is also a new AusPAR for Novartis Pharmaceuticals' Aimovig (erenumab), indicated for prophylaxis of migraine in adults and presented in a pre-filled syringe or pen.
The above article was sent to subscribers in Pharmacy Daily's issue from 26 Sep 19
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 26 Sep 19